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ABSTRACT
Objective To examine the risk of non-fatal idiopathic
venous thromboembolism in current users of a combined
oral contraceptive containing drospirenone, relative to
current users of preparations containing levonorgestrel.
Design Nested case-control study.
Setting UK General Practice Research Database.
Participants Women aged 15-44 years without major risk
factors for venous thromboembolism who started a new
episode of use of an oral contraceptive containing 30 µg
oestrogen in combination with either drospirenone or
levonorgestrel between May 2002 and September 2009.
Cases were women with a first diagnosis of venous
thromboembolism; up to four controls, matched by age,
duration of recorded information, and general practice,
were randomly selected for each case.
Main outcome measures Odds ratios and 95%
confidence intervals estimated with conditional logistic
regression; age adjusted incidence rate ratio estimated
with Poisson regression.
Results 61 cases of idiopathic venous thromboembolism
and 215 matched controls were identified. In the case-
control analysis, current use of the drospirenone
contraceptive was associated with a threefold higher risk
of non-fatal idiopathic venous thromboembolism
compared with levonorgestrel use; the odds ratio
adjusted for body mass index was 3.3 (95% confidence
interval 1.4 to 7.6). Subanalyses suggested that referral,
diagnostic, first time user, duration of use, and switching
biases were unlikely explanations for this finding. The
crude incidence rate was 23.0 (95% confidence interval
13.4to36.9)per100000womanyearsincurrentusersof
drospirenone and 9.1 (6.6 to 12.2) per 100000 woman
years in current users of levonorgestrel oral
contraceptives.The ageadjustedincidencerateratiowas
2.7 (1.5 to 4.7).
Conclusions These findings contribute to emerging
evidencethatthecombinedoralcontraceptivecontaining
drospirenone carries a higher risk of venous
thromboembolism than do formulations containing
levonorgestrel.
INTRODUCTION
In2002aseriesofcasereportsraisedconcernsaboutthe
risk of venous thromboembolism in users of a recently
marketedoralcontraceptivecontaining30µgoestrogen
and a new progestogen, drospirenone.
1 These reports
emergedinthe wakeofearlierfindingsthatoralcontra-
ceptivescontainingthenewerprogestogensdesogestrel
and gestodene (“third generation” pills), and cyproter-
one acetate,carried higher risks ofvenousthromboem-
bolism than did pills containing an older progestogen,
levonorgestrel.
2-7
Since 2002 several studies have explored the risk of
venous thromboembolism in users of the oral contra-
ceptivecontainingdrospirenone.
8-11However, whether
this new oral contraceptive carries a higher risk of
venous thromboembolism than do preparations con-
taininglevonorgestrelremainsuncertain.Two industry
funded cohort studies, which were done to meet post-
marketing surveillance commitments, reported similar
risks of venous thromboembolism in users of drospire-
none and other oral contraceptives.
89However, in one
study, the reference group was not clearly defined and
may have included women who took oral contracep-
tives associated with a higher risk of venous
thromboembolism.
8 In the second study, the rates of
venous thromboembolism in users of contraceptives
containing levonorgestrel were reported to be similar
not only to those in drospirenone users but also to
those in users of other unspecified oral
contraceptives.
9 This last finding is contrary to what
would be expected if that group had included users of
higher risk contraceptives. Two other studies found a
small increase in risk of venous thromboembolism in
usersofthedrospirenoneoralcontraceptivewhencom-
pared with levonorgestrel.
1011 In a Danish registry
based cohortstudy, the relative risk was1.64(95%con-
fidenceinterval1.27to2.10).
10Apopulationbasedcase-
control studyinthe Netherlands reported anoddsratio
of 1.7 (95% confidence interval 0.7 to 3.9).
11
All four studies included some non-idiopathic cases
(women with other known risk factors for venous
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venous thromboembolism not only affects the prob-
ability of the woman developing the condition but
alsoinfluencesdecisionsaboutprescribingoforalcon-
traceptives. Therefore, the inclusion of women with
such risk factors in the study populations makes draw-
ing valid causal inferences more difficult.
12 Secondary
to this, failure to exclude people with other risk factors
for the diseaseof interest can also result in a dilution of
a real effect.
13 For these reasons, the generally pre-
ferred approach in studies of drug safety is to base the
investigation on a study population without major risk
factorsforthedisease.
12Wethereforedidanestedcase-
controlstudytoestimatetheriskofnon-fatalidiopathic
venous thromboembolism associated with current use
oftheoralcontraceptivecontainingdrospirenonerela-
tive to current use of preparations containing levonor-
gestrel.
METHODS
We did a case-control study nested in a cohort of users
of oral contraceptives containing 30 µg oestrogen in
combination with either drospirenone or levonorges-
trel.ThestudywasbasedondatafromtheUKGeneral
Practice Research Database. This database has been
usedpreviouslyinseveralstudiesoforalcontraceptive
use and venous thromboembolism.
357 It contains
information derived from the general practice records
of more than three million people in the United King-
dom, including demographic data and details of
prescribed drugs, medical diagnoses, hospital admis-
sions, and deaths.
Identification of study cohort
As drospirenone first became available in the UK in
April 2002, we confined the study to the years after
this date. We identified all women who had received
at least one prescription for an oral contraceptive con-
taining 30 µg oestrogen in combination with either
drospirenone or levonorgestrel between 1 May 2002
and 30 September 2009 (the study period).
We excluded women if they had a recorded history
of riskfactors forvenousthromboembolism,aswell as
other conditions that might influence decisions about
prescribing of oral contraceptives, such as previous
venous thromboembolism, cancer (except non-
melanoma skin cancer), chronic renal failure, myo-
cardialinfarction,stroke,othercardiovasculardisease,
treated hypertension, treated hyperlipidaemia, type 1
diabetes, ulcerative and other colitis, systemic lupus
erythematosus, rheumatoid arthritis, ankylosing spon-
dylitis and other spondylopathies, psoriatic arthritis,
cystic fibrosis, injecting drug use, and coagulation
defects.
To avoid comparing the risk of venous thromboem-
bolismindissimilargroupsoforalcontraceptiveusers,
onlythosewomenwhostartedanewepisodeofuseofa
studyoralcontraceptiveafter1May2002wereeligible
for inclusion in the study cohort (this included women
who had never used oral contraceptives previously, as
well as those who had used them in the past and were
restarting after a break). We therefore excluded
women whose only use of a study oral contraceptive
during the study period was part of a continuous epi-
sode of oral contraceptive use that had begun before 1
May 2002. We took the date of the first new prescrip-
tion for a study oral contraceptive after 1 May 2002 as
the date of entry into the study cohort.
Toestimatewomanyearsofuseofdrospirenoneand
levonorgestrel oral contraceptives in the study cohort,
we counted the time from the date of the first prescrip-
tion in each episode of use until the end of the last pre-
scription plus 45 days. We considered consecutive
prescriptions for a study oral contraceptive to be part
of the same episode of use if the elapsed time between
theenddateofanyoneprescriptionandtheissueofthe
next did not exceed 100 days.
Identification of potential cases and controls
We carried out all steps in the ascertainment of poten-
tial cases and selection of controls without knowledge
oftheparticularstudyoralcontraceptiveswomenwere
taking.
Cases
Weidentifiedwomenwhohadarecordeddiagnosisof
venous thromboembolism (deep vein thrombosis or
pulmonary embolism) after their entry into the cohort
from the computer records, using the same Read and
OXMIS codes as previously used in studies based on
the General Practice Research Database.
357 We
excludedthosewhodidnothavearecordoftreatment
with an anticoagulant, as well as any women who con-
tinued to receive prescriptions for oral contraceptives
afterthe indexdate,becausethe validityofthediagno-
sis of venous thromboembolism was less certain in
such women. We took the date of diagnosis of venous
thromboembolism as an index date. Women were eli-
gible for inclusion as potential cases if they were aged
15-44yearsontheindexdateandwerecurrentusersof
astudyoralcontraceptive.Wedefinedcurrentusersas
women who received a prescription that would have
extended to the index date or to within 30 days of
thatdate.Wetookcurrentuseastherelevantexposure
period, because the risk of venous thromboembolism
is increased while women are taking oral contracep-
tives and then returns to normal baseline levels once
suchuseisdiscontinued.
14Tobeincludedinthestudy,
current users had to have at least one year of recorded
medicalinformationbeforetheindexdate.Wedefined
the current episodeof use as the continuous episode of
oral contraceptive use that led up to the index date.
This episode could include the use of only one oral
contraceptive or the use of more than one if a woman
switched directly from one oral contraceptive to
another without a break.
Two researchers, blinded to exposure status, inde-
pendentlyreviewedthecomputerisedmedicalrecords
of the potential cases to identify women who had tem-
porary risk factors for venous thromboembolism
shortly before the index date. We excluded women
who had a record of pregnancy, surgery, major injury,
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the index date. Any disagreement between the
reviewers was discussed and a consensus was reached.
Forasubsetoftheremainingpotentialcases(thefirst
42 identified), we sent for copies of hospital discharge
letters or outpatient clinic correspondence (as uncom-
plicated deep vein thrombosis is increasingly being
treated in an outpatient setting in the UK
15) to deter-
minetheproportionforwhomthediagnosisofvenous
thromboembolism could be validated and the propor-
tion in whom no other major risk factors for venous
thromboembolism were present.
Controls
For each eligible case, we randomly selected from the
study cohort up to four controls matched by year of
birth (within two years), number of years of recorded
data, and general practice. The index date of each case
served as the index date for her matched controls. As
withcases,potentialcontrolshadtobecurrentusersof
a study oral contraceptive and to have had at least one
yearofrecordedmedicalinformationbeforetheindex
date. Two researchers, blinded to exposure status,
independently reviewed the computer records of
potential controls. Controls were subject to the same
exclusion criteria as cases.
Statistical analysis
We used conditional logistic regression to compute
odds ratios and 95% confidence intervals in the case-
controlanalyses.Thekeyanalysisestimatedtheriskof
non-fatal idiopathic venous thromboembolism in cur-
rentusers of the oral contraceptive containingdrospir-
enone relative to current users of levonorgestrel
preparations. To do an analysis stratified according to
history of oral contraceptive use (first episode of oral
contraceptive use or previous episodes of use), we also
did an unmatched analysis but accounted for the
matcheddesignbyadjustingforyearofbirthanddura-
tionofrecordedmedicalinformationandadjustingthe
standard error for clustering on general practice. We
used chained equations to impute missing values of
body mass index and smoking status
16-18; we used 100
imputations to obtain stability to one decimal place.
The variables included in the imputation model were
matching variables (year of birth and duration of
recorded information), outcome (deep vein thrombo-
sis,pulmonaryembolism,orcontrol),typeoforalcon-
traceptive (drospirenone or levonorgestrel), and
covariates (log(body mass index), age at index date,
smoking status, current use of antidepressants, history
of varicose veins, history of oral contraceptive use
beforethe currentepisode,durationofthe currentepi-
sode of use, and whether the current episode involved
the use of more than one oral contraceptive).
Potentialconfoundersexploredintheanalysismod-
els were body mass index (as a continuous variable),
history of varicose veins, smoking status (non-smoker,
current smoker, past smoker), and antidepressant use.
We also explored the effect of the duration of the cur-
rent episode of oral contraceptive use. We retained
adjustment for body mass index in all models; we
includedothervariablesiftheyweresignificantpredic-
tors or if their inclusion altered the odds ratio for the
association with type of oral contraceptive by more
than 10%. For the key analysis, we present both com-
plete case and imputed data analyses.
19 We used Stata
version 11.0 for all analyses. We estimated incidence
rates and age standardised rate ratios by using Stata
version 11.0 and Episheet.
20
RESULTS
From the computer records, we identified 65 poten-
tially eligible cases of venous thromboembolism. We
sent for hospital discharge or outpatient clinic letters
for 42 of these women, and we received information
for 31. We excluded four women on the basis of this
extra information. One had a basilic vein thrombosis
that was thought to have an anatomical cause; the
remaining three had confirmed venous thrombo-
embolism with predisposing conditions (anti-
phospholipid syndrome, major trauma, prolonged
immobility).Forafurthertwowomen,theinformation
we received was minimal and we could not determine
whether the diagnosis (deep vein thrombosis in one,
pulmonary embolism in the other) had been made on
thebasisofobjectivetestsorifanyprecipitatingevents
had occurred. We thus included 61 cases in the study;
27 had a diagnosis of deep vein thrombosis alone, and
34 had pulmonary embolism.
Table 1 summarises the characteristics of the 61
cases and 215 controls. The mean age was 32.2 years
for the cases and 31.8 years for the controls. Among
those with a recorded body mass index (93% of cases,
86% of controls), 35 (61%) cases and 57 (31%) controls
had a body mass index of 25 or above. The median
body mass index was 26.1 (range 19.1-45.7) in cases
and 23.3 (17.3-43.2) in controls. Body mass index was
unknown for 34 women (four cases); for five of them
(allcontrols),smokingstatuswasalsounknown.Those
with missing body mass index values were more likely
to have had deep vein thrombosis than pulmonary
embolism(ifcases),beusersoflevonorgestreloralcon-
traceptives,betakingantidepressants,beyounger,and
to be having their first episode of oral contraceptive
use. A slightly smaller proportion of cases than con-
trols were current smokers. Three cases and nine con-
trols had a history of varicose veins; one control had a
history of superficial venous thrombosis. Cases were
more likely to be current users of antidepressants
than were controls.
Table 2showsthe results ofthe key analysis.Seven-
teen (28%) cases and 26 (12%) controls were current
users of the drospirenone oral contraceptive. In the
matched analysis involving all cases and controls, the
unadjusted odd ratio was 3.2 (95% confidence interval
1.5to7.0).Theoddsratioadjustedforbodymassindex
was 3.3 (1.4 to 7.6). Further adjustment for a history of
varicoseveins,smoking,andtheuseofantidepressants
(any antidepressant or tricyclic and non-tricyclic anti-
depressantsseparately)hadanegligibleeffect;theodds
ratio was 3.1 (1.3 to 7.5). In a model that adjusted for
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use, the odds ratio was 3.2 (1.3 to 7.6). These odds
ratios from the imputed missing data analysis were
slightly higher than those obtained in the complete
caseanalysis(theanalysisthatexcludedcasesandcon-
trols with missing body mass index and the controls of
the excluded cases).
Weestimatedseparateassociationsforvalidatedand
unvalidated cases in a model with an interaction term.
After adjustment for body mass index, the odds ratio
for validated cases was 4.0 (0.9 to 16.5) and that for
unvalidated cases was 3.0 (1.0 to 8.5); the P value for
the interaction was 0.8. Further adjustment for anti-
depressant use gave odds ratios of 3.4 (0.8 to 14.9)
and 3.4 (1.2 to 10.1).
Wealsoexaminedtherisksofpulmonaryembolism
and deep vein thrombosis separately; the matched
odds ratio for pulmonary embolism (adjusted for
body mass index) was 2.1 (0.8 to 5.6). The unadjusted
matched estimate for deep vein thrombosis (based on
10 discordant case-control sets) was 8.6 (1.8 to 41.6).
Adjustment for body mass index gave an even higher
odds ratio with a very wide confidence interval, indi-
catingthattheestimatewasunreliableinthissmallsub-
group.
We also did matched analyses to examine whether
the excessrisk of venousthromboembolismin current
users of the drospirenone oral contraceptive, relative
to users of levonorgestrel, differed according to age
(<35 years, ≥35 years); the odds ratios from the inter-
action model (adjusted for body mass index) were 3.7
(1.3 to 10.7) for the younger women and 2.8 (0.7 to
10.7) for the older women; the P value for the inter-
action was 0.7. Further adjustment for antidepressant
use gave odds ratios of 4.1 (1.4 to 12.2) and 2.4 (0.6 to
10.2); the P value was 0.6.
Fourteen (23%) cases and 36 (17%) controls had no
record of any previous oral contraceptive use before
the current episode. We did an analysis to explore
whether the excess risk of venous thromboembolism
associatedwiththeuseofthedrospirenoneoralcontra-
ceptivedifferedaccordingtothehistoryoforalcontra-
ceptive use before the current episode (no previous
use, at least one previous episode of use). Among first
time users, the unmatched odds ratio from the inter-
action model adjusted for the matching factors and
body mass index was 8.6 (1.7 to 42.8). For women
who had previously used oral contraceptives, the cor-
respondingadjustedoddsratiowas2.4(1.1to5.2).The
P value for the interaction was 0.17.
We also did a matched analysis to examine whether
the excessrisk of venousthromboembolismin current
users of the drospirenone contraceptive differed
according to the elapsed time since the product had
been introduced on to the market. We chose a cut-off
date of 1 January 2007 to allow for sufficient woman
years of use of both oral contraceptives to be accumu-
lated. We found elevated risks in the periods before
and afterJanuary2007.Theoddsratiosfrom theinter-
action model (adjusted for body mass index) were 2.2
(0.5to9.2)inthefirstperiodand4.1(1.4to11.8)inthe
second period; the P value for the interaction was 0.5.
Six cases and 17 controls had taken more than one
oral contraceptive in the course of their current epi-
sode of continuous oral contraceptive use. When we
excluded these women, the adjusted (for body mass
index) matched odds ratio was 3.2 (1.1 to 8.7). Adjust-
ment for switching (and body mass index), rather than
excluding these women, produced similar results; the
odds ratio was 3.6 (1.4 to 9.0).
Wefound318825womenwhometallofthecriteria
for inclusion in the study cohort. This cohort had an
estimated73853womanyearsofuseoftheoralcontra-
ceptive containing 30 µg oestrogen and drospirenone
and 482229 woman years of use of preparations con-
taining 30 µg oestrogen and levonorgestrel. The crude
incidence rates were 23.0 (95% confidence interval
13.4 to 36.9) per 100000 woman years in current
users of drospirenone oral contraceptives and 9.1 (6.6
to 12.2) per 100000 woman years in current users of
levonorgestrel oral contraceptives. The age adjusted
incidence rate ratio was 2.7 (1.5 to 4.7).
DISCUSSION
Inthisstudy,womenwhowerecurrentusersoftheoral
contraceptive containing drospirenone were about
three times as likely to develop non-fatal idiopathic
venous thromboembolism as were current users of
contraceptives containing levonorgestrel. The
matched odds ratio (adjusted for body mass index) in
the case-control analysis was 3.3 (95% confidence
interval 1.4 to 7.6), and the age adjusted incidence
rate ratio in the cohort analysis was 2.7 (95% confi-
dence interval 1.5 to 4.7).
Table 1 |Characteristics of cases and controls. Values are numbers (percentages) unless
stated otherwise
Characteristic
Cases
(n=61)
Controls
(n=215)
Unadjusted matched odds ratio
(95% CI)
Mean (SD) age (years) 32.2 (7.2) 31.8 (7.4) –
Body mass index category (kg/m
2):
<20 2 (3) 27 (13) 0.4 (0.1 to 1.7)
20-24.9 20 (33) 101 (47) 1.0
25-29.9 20 (33) 42 (20) 2.4 (1.2 to 4.8)
≥30 15 (25) 15 (7) 5.5 (2.1 to 14.0)
Unknown 4 (7) 30 (14) 0.7 (0.2 to 2.4)
H i s t o r yo fv a r i c o s ev e i n s 3( 5 ) 9( 4 ) 1 . 2( 0 . 3t o4 . 4 )
Smoking status:
Current smoker 11 (18) 47 (22) 0.7 (0.3 to 1.5)
Former smoker 9 (15) 39 (18) 0.7 (0.3 to 1.5)
Non-smoker 41 (67) 124 (58) 1.0
Unknown 0 5 (2) –
Current drug use:
Antipsychotic 0 1 (<1) –
Any antidepressant 7 (11) 11 (5) 2.5 (0.9 to 7.1)
Tricyclic antidepressant 3 (5) 2 (1) 5.1 (0.8 to 30.4)
Non-tricyclic antidepressant 4 (7) 9 (4) 1.6 (0.5 to 5.0)
Tranexamic acid 2 (3) 0 –
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Thestudyhadseveralstrengths.Firstly,wearelikelyto
have identified all potential diagnosed cases of non-
fatal venous thromboembolism in the study cohort,
because information about outpatient and emergency
department visits and hospital admissions in the UK is
sent to general practitioners, and the practices contri-
buting to the General Practice Research Database are
trained to record the diagnoses associated with such
visitsandadmissionsinthepatient’srecord.Secondly,
referral and diagnostic biases seem unlikely explana-
tions for our results, as an elevated risk in users of the
drospirenone oral contraceptive was also apparent in
the analysis confined to cases of pulmonary embolism
—cases in whom the severity of the condition makes
any potential differential referral of users of the newer
oral contraceptive much less likely. Thirdly, for both
cases and controls, information about the medical his-
tory and prescription of oral contraceptives and other
drugs came from medical records and hence was not
subject to recall bias. Body mass index also came from
records, rather than self report. Controls came from
the same general practices as cases and were matched
on the number of years of recorded medical informa-
tion, ensuring comparable quality and duration of
information.Moreover,thedurationofrecordedinfor-
mation was considerable (mean duration 10 years),
permitting the ascertainment of comprehensive medi-
cal and contraceptive histories. Fourthly, we restricted
thestudytocurrentusersofdrospirenoneandlevonor-
gestrelcontraceptiveswhoreceivedprescriptionsfrom
their general practitioners. Although some current
users of oral contraceptives could have been excluded
from this study because they obtained their contracep-
tives from other sources such as family planning
clinics, the risk of venous thromboembolism in users
of the drospirenone contraceptive relative to levonor-
gestreluserswouldneedtobedifferentintheexcluded
group for this to have any relevance to the inter-
pretation of our results. Fifthly, confounding of the
key results by age, body mass index, smoking, conco-
mitant drug use, or underlying medical conditions is
unlikely: we excluded cases and controls with major
risk factors for venous thromboembolism, controls
were matched to cases for year of birth, and we
explored potential confounding in the analysis. We
used multiple imputation methods to impute missing
data for body mass index and smoking; although this
assumes that data are missing at random, non-
ignorable mechanisms that would have had more
than a minimal effect on the estimated odds ratios are
unlikely.
Wedidnothaveinformationaboutfamilyhistoryof
venous thromboembolism, but any difference in the
prevalence of this risk factor between users of drospir-
enone and levonorgestrel contraceptives would be
unlikely to be of sufficient magnitude to explain a
threefold elevated risk. Thus, our results seem very
unlikely to be explained by any selective prescribing
ofthenewerproducttowomenathigherriskofvenous
thromboembolism.Finally,tocomparesimilargroups
ofusers,weconfinedthestudytowomenwhostarteda
new episode of oral contraceptive use after drospire-
nonewas firstavailable foruse. We foundno evidence
that current users of drospirenone as a group included
a disproportionate number of short term or first time
users (who seem to carry a higher risk of venous
thromboembolism
21) than did current users of levo-
norgestrel pills. Moreover, the excess risk associated
with the drospirenone contraceptive persisted after
adjustment for duration of use; it was also apparent
both in first time users and in women who had taken
oralcontraceptivespreviously,anditwaslowerduring
the period after the introduction of drospirenone
(when it might be expected to be higher if drospire-
none users were more likely to be first time users than
were women taking levonorgestrel pills) than in later
years. The point estimate also remained above 3.0
when we took switching into account.
The main limitation of this study was the relatively
small number of cases, which inevitably limited the
precisionofourestimatesofrelativeriskinthesubana-
lyses, as shown by the wide 95% confidence intervals.
Nevertheless, the point estimates obtained in the ana-
lyses stratified by age,certainty of diagnosis, history of
contraceptiveuse,andcalendarperiodwereallconsis-
tently in the order of at least a twofold to threefold
higher risk of venous thromboembolism in users of
the oral contraceptive containing drospirenone rela-
tive to users of levonorgestrel. Moreover, the results
of this study are very similar to those of a larger study
that used data from a US claims database.
22
We did not obtain copies of hospital discharge or
outpatient clinic letters for all potential cases, but in
the subset of women for whom we had such informa-
tion all had confirmed venous thromboembolism and
only four were considered non-idiopathic. This pro-
vides reassurance that virtually all of the women
included in this study are likely to be true cases.
Although some of the women for whom we did not
obtain extra information may have had conditions or
events that precipitated their venous thromboembo-
lism, the proportion is likely to be small and, if any-
thing, the inclusion of such women is likely to have
resulted in a slight attenuation of the estimates of rela-
tive risk. In any event, we found an elevated risk for
validated cases.
Table 2 |Current use of oral contraceptives and venous thromboembolism
Progestogen in oral
contraceptive
Cases
(n=61)
Controls
(n=215)
Unadjusted matched
odds ratio (95% CI)
Adjusted matched
odds ratio (95% CI)*
Multiple imputation analysis†:
Levonorgestrel 44 189 1.0 1.0
Drospirenone 17 26 3.2 (1.5 to 7.0) 3.3 (1.4 to 7.6)
Complete case analysis‡:
Levonorgestrel 42 154 – 1.0
Drospirenone 15 22 – 2.9 (1.1 to 7.4)
*Adjusted for body mass index as continuous variable.
†Missing values for body mass index and smoking are imputed.
‡Effect of multiple imputation is illustrated by presentation of complete case analysis adjusted for body mass
index; cases and controls with missing body mass index are excluded from complete case analysis, as are
controls of excluded cases.
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Ourfindingofahigherriskofnon-fatalvenousthrom-
boembolism in users of oral contraceptives containing
drospirenone, relative to levonorgestrel users, is con-
sistentwiththeresultsoftwopreviousepidemiological
studies.
1011 Our estimateof relativerisk wassomewhat
higher than those reported in the Danish and Dutch
studies,
1011 but some differences in design might
account for this. Unlike the Danish cohort study,
10 we
were able to exclude women with temporary risk fac-
tors for venous thromboembolism, such as surgery,
injury, and immobility, and to explore the influence
of body mass index and smoking. In the Dutch
study,
11 the control group may not have provided a
good estimate of the prevalence of use of different
types of oral contraceptives at the time the cases
occurred—about 40% of controls were partners of
men with venous thromboembolism, and 60% were
selected through random digit dialling; the index
dates for the two groups of controls were the date of
diagnosis of venous thromboembolism in the partner
andthedateofinterview,respectively;andthepropor-
tion of eligible women who participated was not high.
Our results are also consistent with findings from
laboratory based studies in which activated protein C
resistance was shown to be higher in users of the dros-
pirenone oral contraceptive than in users of levonor-
gestrel preparations and of a similar magnitude to that
in users of pills containing desogestrel, gestodene, and
cyproterone acetate.
2324
The investigators in one post-marketing study
reported that obese women were differentially pre-
scribed the drospirenone oral contraceptive in their
predominantly German study population
9; however,
we found no evidence of such differential prescribing
toUKwomeninourstudy.Infact,amongthecontrols
with a recorded body mass index, a slightly lower pro-
portion of drospirenone users had a body mass index
of 25 or above compared with levonorgestrel users
(29% v 31%); the median body mass index in the two
groupswas22.4(range17.9-30.8)and23.3(17.3-43.2).
Conclusions and policy implications
This study adds to emerging evidence that use of the
oral contraceptive containing drospirenone is asso-
ciated with a higher risk of venous thromboembolism
than are preparations containing levonorgestrel. Per-
haps now is the time for a systematic review on this
topic. In the meantime, as no clear evidence exists to
show that the use of the drospirenone pill confers
benefits above those of other oral contraceptives in
preventing pregnancy,
25 treating acne,
26 alleviating
premenstrual syndrome,
27 or avoiding weight gain,
28
prescribing lower risk levonorgestrel preparations as
the first line choice in women wishing to take an oral
contraceptive would seem prudent.
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